Replacement Collaboration Compound definition

Replacement Collaboration Compound or “Replacement Product” means any Collaboration Compound or Product selected by BI for further Development and/or Commercialization which is aimed to replace a Collaboration Compound or Product for which BI, at the same time, definitively terminates further Development and/or Commercialization thereof.
View Source
Replacement Collaboration Compound means a GTx SARM Compound that is selected to replace a Collaboration Compound then under development as described in Section 4.6.
View Source

Examples of Replacement Collaboration Compound in a sentence

  • With the exception of this post-SoPD meeting, the meetings of the Program Steering Committee shall be suspended until the earlier of (a) the Filing with the U.S. Food and Drug Administration of the first Investigational New Drug Application for the first Replacement Collaboration Compound for ZP2929, or (b) the first ethical committee approval of a Phase I Clinical trial for the first Replacement Collaboration Compound for ZP2929.

  • In either of the foregoing events, within forty-five (45) calendar days after the selection of such Additional Collaboration Compound or Replacement Collaboration Compound, then Ortho shall update the then-current Development Plan and Development Budget to provide for Development of such compound.

  • It is understood that in no event shall Ortho be obligated to make the payment due pursuant to this Section 3.2 on any milestone more than once with respect to the same Collaboration Compound (or its "Replacement Collaboration Compound") regardless of the number of different forms or formulations of the Collaboration Compound that are developed[ * ].

  • Furthermore, if the Ortho determines that further Development of Andarine or an Additional Collaboration Compound, if any, is not desirable, then it may select another Collaboration Compound to replace Andarine or such Additional Collaboration Compound (and such replacement compound shall be a "Replacement Collaboration Compound").

  • Other than the milestone payments recited in Section 3.2, Ortho shall not be obligated to make any other milestone payments in connection with Andarine, a Replacement Collaboration Compound, or any Additional Collaboration Compound.

  • The JDC will review and approve, with respect to GTx/Ortho Development, the addition of new indications, the ceasing of Development of Andarine, and the addition of a Replacement Collaboration Compound or an Additional Compound.